Abstract
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor that is frequently overexpressed in several epithelial tumors. The EGFR was among the first cell membrane growth factor receptor to be proposed for cancer therapy and two EGFR targeted pharmacologic approaches have been successfully developed: monoclonal antibodies (MAbs) and small molecule inhibitors of the EGFR tyrosine kinase enzymatic activity (TKIs). These approaches have been tested in several human cancers, such as non small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck cancer and pancreatic cancer. However, only a subset of cancer patients will eventually benefit for the treatment with EGFR inhibitors. Therefore, the identification and the clinical validation of criteria for identifying patients which could more likely have a therapeutic advantage from the treatment with these drugs is a urgent clinical need. In the past few years, a series of reports have suggested that certain clinico-pathologic characteristics as well as specific gene alterations of the EGFR and of other genes such as K-RAS could help to identify patients whose cancers could be either sensitive or resistant to EGFR inhibitor therapy. Here we review the available clinical data which could help in defining a strategy to select patients for a more effective therapeutic use of anti-EGFR drugs.
Keywords: EGFR, erlotinib, gefitinib, cetuximab, panitumumab
Current Signal Transduction Therapy
Title: Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Volume: 3 Issue: 3
Author(s): Maria Anna Bareschino, Clorinda Schettino, Linda Alvino, Cesare Gridelli and Fortunato Ciardiello
Affiliation:
Keywords: EGFR, erlotinib, gefitinib, cetuximab, panitumumab
Abstract: The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor that is frequently overexpressed in several epithelial tumors. The EGFR was among the first cell membrane growth factor receptor to be proposed for cancer therapy and two EGFR targeted pharmacologic approaches have been successfully developed: monoclonal antibodies (MAbs) and small molecule inhibitors of the EGFR tyrosine kinase enzymatic activity (TKIs). These approaches have been tested in several human cancers, such as non small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck cancer and pancreatic cancer. However, only a subset of cancer patients will eventually benefit for the treatment with EGFR inhibitors. Therefore, the identification and the clinical validation of criteria for identifying patients which could more likely have a therapeutic advantage from the treatment with these drugs is a urgent clinical need. In the past few years, a series of reports have suggested that certain clinico-pathologic characteristics as well as specific gene alterations of the EGFR and of other genes such as K-RAS could help to identify patients whose cancers could be either sensitive or resistant to EGFR inhibitor therapy. Here we review the available clinical data which could help in defining a strategy to select patients for a more effective therapeutic use of anti-EGFR drugs.
Export Options
About this article
Cite this article as:
Bareschino Anna Maria, Schettino Clorinda, Alvino Linda, Gridelli Cesare and Ciardiello Fortunato, Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer, Current Signal Transduction Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157436208785699668
DOI https://dx.doi.org/10.2174/157436208785699668 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery The Medical Use of Wheatgrass: Review of the Gap Between Basic and Clinical Applications
Mini-Reviews in Medicinal Chemistry Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression
Recent Patents on Anti-Cancer Drug Discovery Serum HSP90-Alpha and Oral Squamous Cell Carcinoma: A Prospective Biomarker
Protein & Peptide Letters Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets Microtubule-targeting Anticancer Agents from Marine Natural Substance
Anti-Cancer Agents in Medicinal Chemistry Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China
Current Gene Therapy Managing Skin Malignancies- How Family Doctors, Plastic Surgeons, and Dermatologists Can Help
Current Cancer Therapy Reviews Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy
Current Pharmaceutical Design Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Evaluation of Tissue and Serum Expression Levels of Lactate Dehydrogenase Isoenzymes in Patients with Head and Neck Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
Current Drug Targets Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism